Search by...
-
28MarSperimentazioni cliniche decentralizzate: l’Ue raccomanda procedure uniformiLo scorso 13 dicembre la Commissione europea, i vertici delle agenzie per i medicinali nazionali e l’Agenzia europea per i medicinali hanno pubblicato un documento dal titolo Recommendation paper on decentralised elements in clinical trials.
-
-
21DecClinical trials and sanctions in relation to Regulation 2014/536, national rules, and contract standardsThe European rules on drug trials do not include provisions for sanctions, but instead leave it up to Member States to outline an effective sanctioning framework.
-
-
1DecReuse of personal data for research purposes in light of the most recent guidelines from the GaranteIn the context of clinical studies, companies are concerned about the legal conditions for use for research purposes of previously collected personal data, including data from third parties.
-
-
20OctIRCCS reform: Upcoming changes with regard to researchThe regulation of Scientific Institutes for Research, Hospitalization, and Health Care (“Istituti di Ricovero e Cura a Carattere Scientifico,” “IRCCS” or “Institutes”) is undergoing a major transformation in Italy.
-
-
21SepDecentralized clinical trials: The current scenario and forthcoming European guidelinesOn August 30, the European Commission (EC), heads of medicines agencies (HMAs), and European Medicines Agency (EMA) published the 2022-2026 work plan for the Accelerating Clinical Trials in the EU (ACT EU) initiative.
-
-
17MarThe new decree on non-profit studies: Data and results may now be soldOn February 16, 2022, more than two years later than planned, the Ministerial Decree of November 30, 2021, containing measures to facilitate and support the development of nonprofit clinical trials of medicinal products and observational studies, as well as to regulate the transfer of data and results of nonprofit trials for registration purposes, was finally published in the Official Gazette.
-
